2 card poker game Netflix 'totally ready' for XMas NFL games, WWESindh govt unveils plan to address power challengesDoughty scores 17 in Indiana State’s 83-80 win against Iona

None

Porter's 26 lead Middle Tennessee over South Florida 95-88BILLERICA, Mass.--(BUSINESS WIRE)--Nov 22, 2024-- Quanterix Corporation (NASDAQ: QTRX) today announced that it received a notice (the “Notice”) on November 21, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the “Form 10-Q"), it is no longer in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the “SEC”). The Notice has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq. Under Nasdaq rules, the Company has 60 calendar days from receipt of the Notice, or until January 20, 2025, to submit a plan to regain compliance with the Rule. On November 12, 2024, the Company previously announced that it would be delayed in filing the Form 10-Q due to the need to restate the Company’s audited consolidated financial statements as of December 31, 2023 and 2022 and for each of the three years in the period ended December 31, 2023, and its unaudited consolidated financial statements for the quarterly and year-to-date (as applicable) periods ended March 31, 2022, June 30, 2022, September 30, 2022, March 31, 2023, June 30, 2023, September 30, 2023, March 31, 2024 and June 30, 2024. The Notice from Nasdaq is standard practice in the event of a delayed periodic financial report filing and was anticipated. The Company is continuing to work expeditiously to complete the filing of the Form 10-Q and remains on track to complete the restatement and all required filings by the end of 2024. This announcement is made in compliance with Nasdaq Listing Rule 5250(b)(2). About Quanterix From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa ® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,100 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this press release are based on Quanterix’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’s actual results to differ from those expressed or implied in the forward-looking statements in this press release include, but are not limited to, that the Company may have underestimated the scope and impact of the restatement of certain of its financial statement and the risk that the Company’s restated financial statements may take longer to complete than expected, as well as those described in our periodic reports filed with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. View source version on businesswire.com : https://www.businesswire.com/news/home/20241122959546/en/ CONTACT: Media: media@quanterix.comInvestor Relations: Amy Achorn (978) 488-1854 ir@quanterix.com KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH TECHNOLOGY HEALTH MEDICAL DEVICES SOURCE: Quanterix Corporation Copyright Business Wire 2024. PUB: 11/22/2024 05:00 PM/DISC: 11/22/2024 05:02 PM http://www.businesswire.com/news/home/20241122959546/en

The Samsung phone I recommend to most people is $100 off during post-Cyber Monday salesMia Syn, MS, Registered Dietician Nutritionist partners with DS Simon Media, Almond Breeze, Mediheal, and Mucinex COMBAT HOLIDAY CONGESTION "So many of us look forward to holiday parties and quality time with loved ones,” says Syn, "But we often find ourselves battling sinus congestion from dry air, cold weather, or seasonal allergies.” Her go-to solution? The NEW Mucinex® Sinus Saline Nasal Spray, the first-ever saline product featuring a 2-in-1 nozzle with customizable spray settings. Consumers can choose the 'Power Jet' to tackle tough nasal congestion or the 'Gentle Mist' to clear everyday congestion and soothe your nose. With its dual-nozzle technology, Mucinex® Sinus Saline Nasal Spray helps relieve congestion caused by allergens, irritants, and colds. Available at major retailers, pharmacies, and on Amazon, you can find your nearest store at Mucinex.com. Direct link: https://www.mucinex.com/ Social Media Handle: Facebook: @mucinex IG: @mucinex_us HOLIDAY TREATS WITH A HEALTHY TWIST Syn also encourages swapping ingredients in traditional holiday recipes with better-for-you alternatives. "One of my favorite holiday ingredients is Almond Breeze Almondmilk,” she shares. Direct link: www.AlmondBreeze.com Social Media Handle: Facebook: Almond Breeze Instagram: @AlmondBreeze Twitter: @AlmondBreeze SKINCARE MUST-HAVES FOR WINTER Cold, harsh air can wreak havoc on your skin, causing dryness and accentuating fine lines. "Nobody enjoys that itchy, uncomfortable feeling that winter brings," says Syn, a skincare enthusiast. "That's why I turn to Mediheal-a trusted name in Korean skincare that's been raising the bar for years." Mediheal's toner pads have become a hit on social media, especially on TikTok, where users are swearing by their magic. Leading the charge are two fan-favorite products: Direct link: Mediheal Amazon Website Social Media Handle: Facebook: @Mediheal US Instagram: @mediheal_us TikTok: @mediheal_us Twitter (X): @medihealus About YourUpdateTV : YourUpdateTV is a property of D S Simon Media. The video included and release was part of a media tour that was produced by D S Simon Media on behalf of Almond Breeze, Mediheal, and Mucinex. Media Contact: Michael O'Donnell D S Simon Media 212-736-2727 [email protected] A video accompanying this release is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/74283b19-564e-43c4-a467-440c7d109074Budget set at 4.99%, eliminating dust suppression and selling off Clearville ParkMANCHESTER, England : New Manchester United's manager Ruben Amorim is known for an ability to connect with players that many say his predecessor Erik ten Hag did not possess, but the 39-year-old thinks he can be stern when he needs to be. The Portuguese cut a charismatic figure in his first press conference as United head coach on Friday, and his warm rapport especially with the nine journalists who travelled from Portugal only added to his reputation for genuine likeability. But asked if he also has a ruthless side that might be needed to restore a team languishing 13th in the Premier League table ahead of Sunday's match at Ipswich Town to former glory, the former Sporting manager said it was possible to be both. "You can be the same person. There are some places to have fun. There are some places to work hard. So I can be ruthless when I have to be," Amorim said. "If you think as a team, I will be the nicest guy that you have ever seen. If there is someone just thinking for himself, I will be a different person. And I'm not like that kind of guy that wants to show that he's the boss. "They will feel it in the small details that I can be the smiling one, but then, when you have to job to do, I will be a different person, and they understand that." Amorim, known as the "poet" by Portugal and former United forward Cristiano Ronaldo for his communication skills, also erased concerns raised by British media about his English with his thoughtful answers on Friday. He stumbled only once, over the word "suspicious". Because of the international break, Amorim had only two training sessions with his squad before they take the pitch at Portman Road on Sunday ahead of a gruelling stretch of games. It is not how he would have planned his early days with his new team. "It's so much harder to come to a team in the middle of the season, because you have to get to know the players during the games," Amorim said. "(But) it depends. If you are winning, it's a lot of fun having a lot of games, trying to make some changes tactically and winning games. But if you are losing, you don't have the time in training to work out everything you want to work." Following the clash with 17th-placed Ipswich, they host Bodo/Glimt in Amorim's first game at Old Trafford, and entertain Everton in the league. The three matches are part of a packed schedule of 12 games in six weeks. "Where you can improve a team is in training. This is the most important aspect... it is really hard to do it on video or in recovering trainings," Amorim said. "But we will find ways to try to cope with that."

Cutting in line? American Airlines’ new boarding tech might stop you at now over 100 airports

Netflix continues to express confidence that its streaming platform is prepared to handle the massive audiences expected for a pair of Christmas Day NFL games along with the start of its live coverage of the World Wrestling Entertainment's "Raw" next month. Concerns were raised after users experienced issues with buffering and low quality feeds during the Jake Paul-Mike Tyson boxing match last month. Netflix has exclusive rights to stream NFL games on Christmas Day between the Kansas City Chiefs at the Pittsburgh Steelers and the Baltimore Ravens at the Houston Texans. Beyonce is scheduled to perform during halftime of the Ravens-Texans game, which could create more server traffic Netflix must take into account. It's a major test after the company reported an average global live audience of 108 million viewers for Paul's victory over Tyson in Arlington, Texas. Downdetector.com , which tracks service outages, announced that there were 90,000 issues reported at one point. "It was a big number, but you don't know, and you can't learn these things until you do them, so you take a big swing," Netflix chief content officer Bela Bajaria told Front Office Sports. "Our teams and our engineers are amazing, moved super quickly, and stabilized it, and many of the members had it back up and running pretty quickly. But we learn from these things. "We've all obviously done a lot of stuff to learn and get ready for the NFL and Beyonce, and so we're totally ready and excited for WWE." WWE president Nick Khan told FOS that Raw's tone and content will not change as it moves to the streaming service, with its first event of 2025 scheduled for Jan. 6. "There's some online chatter about, ‘oh, it's going to be R-rated, or for us old folks, X-rated.' That's definitely not happening," Khan said. "It's family-friendly, multi-generational, advertiser-friendly programming. It's going to stay that way. I would look for more global flair, especially as the relationship continues to develop." --Field Level Media

Richard BrumfieldLetters for Dec. 1: Short-term help needed for area’s homeless population

My husband cheated on me with his own brother – they shared ‘steamy’ messages, it happened while I was in the same house

SANTA CLARA, Calif. , Dec. 3, 2024 /PRNewswire/ -- Couchbase, Inc. BASE , the developer data platform for critical applications in our AI world, today announced financial results for its third quarter ended October 31, 2024. "I'm pleased with the continued operational progress of the entire Couchbase team," said Matt Cain , Chair, President and CEO of Couchbase. "We delivered top- and bottom-line results that exceeded our outlook, and we achieved another significant milestone with Capella, which now represents 15.1% of our ARR and one third of our customer base. I remain highly confident in our outlook and ability to achieve our objectives in fiscal 2025." Third Quarter Fiscal 2025 Financial Highlights Revenue: Total revenue for the quarter was $51.6 million , an increase of 13% year-over-year. Subscription revenue for the quarter was $49.3 million , an increase of 12% year-over-year. Annual recurring revenue (ARR): Total ARR as of October 31, 2024 was $220.3 million , an increase of 17% year-over-year, or 16% on a constant currency basis. See the section titled "Key Business Metrics" below for details. Gross margin: Gross margin for the quarter was 87.3%, compared to 88.8% for the third quarter of fiscal 2024. Non-GAAP gross margin for the quarter was 88.2%, compared to 89.5% for the third quarter of fiscal 2024. See the section titled "Use of Non-GAAP Financial Measures" and the tables titled "Reconciliation of GAAP to Non-GAAP Results" below for details. Loss from operations: Loss from operations for the quarter was $19.2 million , compared to $17.5 million for the third quarter of fiscal 2024. Non-GAAP operating loss for the quarter was $3.5 million , compared to $5.0 million for the third quarter of fiscal 2024. Cash flow: Cash flow used in operating activities for the quarter was $16.9 million , compared to cash flow used in operating activities of $12.7 million in the third quarter of fiscal 2024. Capital expenditures were $0.6 million during the quarter, leading to negative free cash flow of $17.5 million , compared to negative free cash flow of $13.8 million in the third quarter of fiscal 2024. Remaining performance obligations (RPO): RPO as of October 31, 2024 was $211.3 million , an increase of 29% year-over-year. Recent Business Highlights Announced Capella AI Services to provide the critical capabilities and tools required for our customers to streamline the development of agentic AI applications. The new AI Services include model hosting, automated vectorization, unstructured data preprocessing and AI agent catalog services, allowing organizations to prototype, build, test and deploy AI agents while keeping models and data close together on one unified platform. Couchbase's innovation and newest features with AI Services are on display at AWS re:Invent this week. Continued to advance the Couchbase platform with three major releases: Capella Columnar which converges operational and real-time analytics; Mobile with vector search which makes it possible for businesses to offer similarity and hybrid search in their applications on mobile and at the edge; and Capella Free Tier, a workspace which empowers developers to work faster. Expanded Couchbase's AI partner ecosystem through new and recently introduced integrations with industry leaders including Amazon Bedrock, Azure OpenAI, Google Vertex AI, Haystack, LangChain, LlamaIndex, NVIDIA NIM/NeMo, Unstructured.io, Vectorize and others. These integrations help empower our customers to more easily develop enterprise-class, RAG-based solutions and meet their specific deployment needs. Recognized innovative Couchbase customer achievements through the 2024 Customer Impact Awards, demonstrating how leading companies are leveraging Couchbase's technology to transform their operations. For one of the award recipients – a leading software and technology company that powers the global travel industry serving a wide range of travel companies including airlines, hoteliers, travel agencies and other suppliers – Couchbase will enable a distributed, always-on transactional system. Couchbase handles hundreds of thousands of read transactions and more than 1,000 updates per second for this customer. Financial Outlook For the fourth quarter and full year of fiscal 2025, Couchbase expects: Q4 FY2025 Outlook FY2025 Outlook Total Revenue $52.7-53.5 million $207.2-208.0 million Total ARR $236.5-239.5 million $236.5-239.5 million Non-GAAP Operating Loss $5.7-4.7 million $20.0-19.0 million The guidance provided above is based on several assumptions that are subject to change and many of which are outside our control. If actual results vary from these assumptions, our expectations may change. There can be no assurance that we will achieve these results. Couchbase is not able, at this time, to provide GAAP targets for operating loss for the fourth quarter or full year of fiscal 2025 because of the difficulty of estimating certain items excluded from non-GAAP operating loss that cannot be reasonably predicted, such as charges related to stock-based compensation expense. The effect of these excluded items may be significant. Conference Call Information Couchbase will host a live webcast at 1:30 p.m. Pacific Time (or 4:30 p.m. Eastern Time ) on Tuesday, December 3, 2024, to discuss its financial results and business highlights. The conference call can be accessed by dialing 877-407-8029 from the United States , or +1 201-689-8029 from international locations. The live webcast and a webcast replay can be accessed from the investor relations page of Couchbase's website at investors.couchbase.com . About Couchbase As industries race to embrace AI, traditional database solutions fall short of rising demands for versatility, performance and affordability. Couchbase is seizing the opportunity to lead with Capella, the developer data platform for critical applications in our AI world. By uniting transactional, analytical, mobile and AI workloads into a seamless, fully-managed solution, Couchbase empowers developers and enterprises to build and scale applications with complete flexibility – delivering exceptional performance, scalability and cost-efficiency from cloud to edge and everything in between. Trusted by over 30% of the Fortune 100, Couchbase enables organizations to unlock innovation, accelerate AI transformation and redefine customer experiences wherever they happen. Discover why Couchbase is the foundation of critical everyday applications by visiting www.couchbase.com and following us on LinkedIn and X . Couchbase has used, and intends to continue using, its investor relations website and the corporate blog at blog.couchbase.com to disclose material non-public information and to comply with its disclosure obligations under Regulation FD. Accordingly, you should monitor our investor relations website and the corporate blog in addition to following our press releases, SEC filings and public conference calls and webcasts. Use of Non-GAAP Financial Measures In addition to our financial information presented in accordance with GAAP, we believe certain non-GAAP financial measures are useful to investors in evaluating our operating performance. We use certain non-GAAP financial measures, collectively, to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that non-GAAP financial measures, when taken together with the corresponding GAAP financial measures, may be helpful to investors because they provide consistency and comparability with past financial performance and meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations or outlook. Non-GAAP financial measures are presented for supplemental informational purposes only, have limitations as analytical tools and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP, and may be different from similarly-titled non-GAAP financial measures used by other companies. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures (provided in the financial statement tables included in this press release), and not to rely on any single financial measure to evaluate our business. Non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating loss, non-GAAP operating margin, non-GAAP net loss and non-GAAP net loss per share: We define these non-GAAP financial measures as their respective GAAP measures, excluding expenses related to stock-based compensation expense, employer payroll taxes on employee stock transactions, restructuring charges and impairment of capitalized internal-use software. We use these non-GAAP financial measures in conjunction with GAAP measures to assess our performance, including in the preparation of our annual operating budget and quarterly forecasts, to evaluate the effectiveness of our business strategies and to communicate with our board of directors concerning our financial performance. For the fourth quarter of fiscal 2024, we excluded the impairment of capitalized internal-use software, a non-cash operating expense, from our non-GAAP results as it is not reflective of ongoing operating results. This impairment charge related to certain previously capitalized internal-use software that we determined would no longer be placed into service. Prior period non-GAAP financial measures have not been adjusted to reflect this change as we did not incur impairment of capitalized internal-use software in any prior period presented. Free cash flow: We define free cash flow as cash used in operating activities less additions to property and equipment, which includes capitalized internal-use software costs. We believe free cash flow is a useful indicator of liquidity that provides our management, board of directors and investors with information about our future ability to generate or use cash to enhance the strength of our balance sheet and further invest in our business and pursue potential strategic initiatives. Please see the reconciliation tables at the end of this press release for the reconciliation of GAAP and non-GAAP results. Key Business Metrics We review a number of operating and financial metrics, including ARR, to evaluate our business, measure our performance, identify trends affecting our business, formulate business plans and make strategic decisions. We define ARR as of a given date as the annualized recurring revenue that we would contractually receive from our customers in the month ending 12 months following such date. Based on historical experience with customers, we assume all contracts will be renewed at the same levels unless we receive notification of non-renewal and are no longer in negotiations prior to the measurement date. For Capella products, ARR in a customer's initial year is calculated as the greater of: (i) initial year contract revenue as described above or (ii) annualized prior 90 days of actual consumption; and ARR for subsequent years is calculated with method (ii). ARR excludes services revenue. Prior to fiscal 2025, ARR excluded on-demand revenue and, for Capella products in a customer's initial year, ARR was calculated solely on the basis of initial year contract revenue. The reason for these changes is to better reflect ARR where usage rates or timing of purchases may be uneven and to better align with how ARR is used to measure the performance of the business. ARR for prior periods has not been adjusted to reflect this change as it is not material to any period previously presented. ARR should be viewed independently of revenue, and does not represent our revenue under GAAP on an annualized basis, as it is an operating metric that can be impacted by contract start and end dates and renewal dates. ARR is not intended to be a replacement for forecasts of revenue. Although we seek to increase ARR as part of our strategy of targeting large enterprise customers, this metric may fluctuate from period to period based on our ability to acquire new customers, expand within our existing customers and consumption dynamics. We believe that ARR is an important indicator of the growth and performance of our business. We also attempt to represent the changes in the underlying business operations by eliminating fluctuations caused by changes in foreign currency exchange rates within the current period. We calculate constant currency growth rates by applying the applicable prior period exchange rates to current period results. Forward-Looking Statements This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on management's beliefs and assumptions and on information currently available to management. Forward-looking statements include, but are not limited to, quotations of management, the section titled "Financial Outlook" above and statements about the expected client demand for and benefits of our offerings, the impact of our recently-released and planned products and services and our market position, strategies and potential market opportunities. Forward-looking statements generally relate to future events or our future financial or operating performance. Forward-looking statements include all statements that are not historical facts and, in some cases, can be identified by terms such as "anticipate," "expect," "intend," "plan," "believe," "continue," "could," "potential," "remain," "may," "might," "will," "would" or similar expressions and the negatives of those terms. However, not all forward-looking statements contain these identifying words. Forward-looking statements involve known and unknown risks, uncertainties and other factors, including factors beyond our control, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to: our history of net losses and ability to achieve or maintain profitability in the future; our ability to continue to grow on pace with historical rates; our ability to manage our growth effectively; intense competition and our ability to compete effectively; cost-effectively acquiring new customers or obtaining renewals, upgrades or expansions from our existing customers; the market for our products and services being highly competitive and evolving, and our future success depending on the growth and expansion of this market; our ability to innovate in response to changing customer needs, new technologies or other market requirements, including new capabilities, programs and partnerships and their impact on our customers and our business; our limited operating history, which makes it difficult to predict our future results of operations; the significant fluctuation of our future results of operations and ability to meet the expectations of analysts or investors; our significant reliance on revenue from subscriptions, which may decline and, the recognition of a significant portion of revenue from subscriptions over the term of the relevant subscription period, which means downturns or upturns in sales are not immediately reflected in full in our results of operations; and the impact of geopolitical and macroeconomic factors. Further information on risks that could cause actual results to differ materially from forecasted results are included in our filings with the Securities and Exchange Commission that we may file from time to time, including those more fully described in our Annual Report on Form 10-K for the fiscal year ended January 31, 2024 . Additional information will be made available in our Quarterly Report on Form 10-Q for the quarter ended October 31, 2024 that will be filed with the Securities and Exchange Commission, which should be read in conjunction with this press release and the financial results included herein. Any forward-looking statements contained in this press release are based on assumptions that we believe to be reasonable as of this date. Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements. Couchbase, Inc. Condensed Consolidated Statements of Operations (in thousands, except per share data) (unaudited) Three Months Ended October 31, Nine Months Ended October 31, 2024 2023 2024 2023 Revenue: License $ 4,343 $ 4,577 $ 16,444 $ 14,318 Support and other 44,955 39,420 131,185 109,175 Total subscription revenue 49,298 43,997 147,629 123,493 Services 2,330 1,816 6,915 6,455 Total revenue 51,628 45,813 154,544 129,948 Cost of revenue: Subscription (1) 4,866 3,549 13,278 11,067 Services (1) 1,690 1,562 5,423 5,875 Total cost of revenue 6,556 5,111 18,701 16,942 Gross profit 45,072 40,702 135,843 113,006 Operating expenses: Research and development (1) 17,486 15,903 52,703 47,578 Sales and marketing (1) 34,196 31,602 108,119 96,503 General and administrative (1) 12,624 10,739 37,843 30,823 Restructuring (1) — — — 46 Total operating expenses 64,306 58,244 198,665 174,950 Loss from operations (19,234) (17,542) (62,822) (61,944) Interest expense (17) — (46) (43) Other income, net 1,790 1,298 5,062 3,986 Loss before income taxes (17,461) (16,244) (57,806) (58,001) Provision for income taxes 691 11 1,236 780 Net loss $ (18,152) $ (16,255) $ (59,042) $ (58,781) Net loss per share, basic and diluted $ (0.35) $ (0.34) $ (1.16) $ (1.26) Weighted-average shares used in computing net loss per share, basic and diluted 51,831 47,586 50,821 46,724 (1) Includes stock-based compensation expense as follows: Three Months Ended October 31, Nine Months Ended October 31, 2024 2023 2024 2023 Cost of revenue—subscription $ 318 $ 130 $ 885 $ 559 Cost of revenue—services 104 119 354 413 Research and development 4,497 3,116 12,704 9,498 Sales and marketing 5,242 4,188 16,627 11,461 General and administrative 5,127 4,202 15,501 11,216 Restructuring — — — 1 Total stock-based compensation expense $ 15,288 $ 11,755 $ 46,071 $ 33,148 Couchbase, Inc. Condensed Consolidated Balance Sheets (in thousands) (unaudited) As of October 31, 2024 As of January 31, 2024 Assets Current assets Cash and cash equivalents $ 33,031 $ 41,351 Short-term investments 108,908 112,281 Accounts receivable, net 28,514 44,848 Deferred commissions 13,297 15,421 Prepaid expenses and other current assets 10,551 10,385 Total current assets 194,301 224,286 Property and equipment, net 7,000 5,327 Operating lease right-of-use assets 5,497 4,848 Deferred commissions, noncurrent 14,485 11,400 Other assets 1,176 1,891 Total assets $ 222,459 $ 247,752 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 4,724 $ 4,865 Accrued compensation and benefits 12,323 18,116 Other accrued expenses 3,981 4,581 Operating lease liabilities 2,150 3,208 Deferred revenue 67,996 81,736 Total current liabilities 91,174 112,506 Operating lease liabilities, noncurrent 3,678 2,078 Deferred revenue, noncurrent 829 2,747 Total liabilities 95,681 117,331 Stockholders' equity Preferred stock — — Common stock — — Additional paid-in capital 676,360 621,024 Accumulated other comprehensive income 119 56 Accumulated deficit (549,701) (490,659) Total stockholders' equity 126,778 130,421 Total liabilities and stockholders' equity $ 222,459 $ 247,752 Couchbase, Inc. Condensed Consolidated Statements of Cash Flows (in thousands) (unaudited) Three Months Ended October 31, Nine Months Ended October 31, 2024 2023 2024 2023 Cash flows from operating activities Net loss $ (18,152) $ (16,255) $ (59,042) $ (58,781) Adjustments to reconcile net loss to net cash used in operating activities Depreciation and amortization 757 399 1,520 2,034 Stock-based compensation, net of amounts capitalized 15,288 11,755 46,071 33,148 Amortization of deferred commissions 4,375 4,500 12,655 13,742 Non-cash lease expense 863 765 2,393 2,313 Foreign currency transaction losses (gains) (60) 484 231 649 Other (456) (804) (1,869) (2,580) Changes in operating assets and liabilities Accounts receivable 2,912 1,577 16,207 9,114 Deferred commissions (5,367) (4,746) (13,616) (13,892) Prepaid expenses and other assets (606) 955 (163) 837 Accounts payable (295) (10) (149) 1,735 Accrued compensation and benefits (1,799) (1,763) (5,790) (3,517) Other Accrued Expenses 632 (1,126) (475) (2,997) Operating lease liabilities (876) (838) (2,501) (2,561) Deferred revenue (14,111) (7,636) (15,658) 313 Net cash used in operating activities (16,895) (12,743) (20,186) (20,443) Cash flows from investing activities Purchases of short-term investments (37,809) (26,141) (75,614) (90,456) Maturities of short-term investments 23,000 41,854 81,144 111,974 Additions to property and equipment (583) (1,066) (2,645) (3,425) Net cash (used in) provided by investing activities (15,392) 14,647 2,885 18,093 Cash flows from financing activities Proceeds from exercise of stock options 1,115 2,703 5,251 7,353 Proceeds from issuance of common stock under ESPP 1,720 1,153 3,515 2,000 Net cash provided by financing activities 2,835 3,856 8,766 9,353 Effect of exchange rate changes on cash, cash equivalents and restricted cash (124) (290) (328) (542) Net (decrease) increase in cash, cash equivalents and restricted cash (29,576) 5,470 (8,863) 6,461 Cash, cash equivalents, and restricted cash at beginning of period 62,607 41,980 41,894 40,989 Cash, cash equivalents, and restricted cash at end of period $ 33,031 $ 47,450 $ 33,031 $ 47,450 Reconciliation of cash, cash equivalents, and restricted cash within the consolidated balance sheets to the amounts shown above: Cash and cash equivalents $ 33,031 $ 46,907 $ 33,031 $ 46,907 Restricted cash included in other assets — 543 — 543 Total cash, cash equivalents and restricted cash $ 33,031 $ 47,450 $ 33,031 $ 47,450 Couchbase, Inc. Reconciliation of GAAP to Non-GAAP Results (in thousands, except per share data) (unaudited) Three Months Ended October 31, Nine Months Ended October 31, 2024 2023 2024 2023 Reconciliation of GAAP gross profit to non-GAAP gross profit: Total revenue $ 51,628 $ 45,813 $ 154,544 $ 129,948 Gross profit $ 45,072 $ 40,702 $ 135,843 $ 113,006 Add: Stock-based compensation expense 422 249 1,239 972 Add: Employer taxes on employee stock transactions 22 55 120 86 Non-GAAP gross profit $ 45,516 $ 41,006 $ 137,202 $ 114,064 Gross margin 87.3 % 88.8 % 87.9 % 87.0 % Non-GAAP gross margin 88.2 % 89.5 % 88.8 % 87.8 % Three Months Ended October 31, Nine Months Ended October 31, 2024 2023 2024 2023 Reconciliation of GAAP operating expenses to non-GAAP operating expenses: GAAP research and development $ 17,486 $ 15,903 $ 52,703 $ 47,578 Less: Stock-based compensation expense (4,497) (3,116) (12,704) (9,498) Less: Employer taxes on employee stock transactions (106) (199) (585) (430) Non-GAAP research and development $ 12,883 $ 12,588 $ 39,414 $ 37,650 GAAP sales and marketing $ 34,196 $ 31,602 $ 108,119 $ 96,503 Less: Stock-based compensation expense (5,242) (4,188) (16,627) (11,461) Less: Employer taxes on employee stock transactions (275) (327) (1,378) (777) Non-GAAP sales and marketing $ 28,679 $ 27,087 $ 90,114 $ 84,265 GAAP general and administrative $ 12,624 $ 10,739 $ 37,843 $ 30,823 Less: Stock-based compensation expense (5,127) (4,202) (15,501) (11,216) Less: Employer taxes on employee stock transactions (64) (176) (391) (264) Non-GAAP general and administrative $ 7,433 $ 6,361 $ 21,951 $ 19,343 Three Months Ended October 31, Nine Months Ended October 31, 2024 2023 2024 2023 Reconciliation of GAAP operating loss to non-GAAP operating loss: Total revenue $ 51,628 $ 45,813 $ 154,544 $ 129,948 Loss from operations $ (19,234) $ (17,542) $ (62,822) $ (61,944) Add: Stock-based compensation expense 15,288 11,755 46,071 33,147 Add: Employer taxes on employee stock transactions 467 757 2,474 1,557 Add: Restructuring (2) — — — 46 Non-GAAP operating loss $ (3,479) $ (5,030) $ (14,277) $ (27,194) Operating margin (37) % (38) % (41) % (48) % Non-GAAP operating margin (7) % (11) % (9) % (21) % Three Months Ended October 31, Nine Months Ended October 31, 2024 2023 2024 2023 Reconciliation of GAAP net loss to non-GAAP net loss: Net loss $ (18,152) $ (16,255) $ (59,042) $ (58,781) Add: Stock-based compensation expense 15,288 11,755 46,071 33,147 Add: Employer taxes on employee stock transactions 467 757 2,474 1,557 Add: Restructuring (2) — — — 46 Non-GAAP net loss $ (2,397) $ (3,743) $ (10,497) $ (24,031) GAAP net loss per share $ (0.35) $ (0.34) $ (1.16) $ (1.26) Non-GAAP net loss per share $ (0.05) $ (0.08) $ (0.21) $ (0.51) Weighted average shares outstanding, basic and diluted 51,831 47,586 50,821 46,724 (2) For the nine months ended October 31, 2023, an immaterial amount of stock-based compensation expense related to restructuring charges was included in the restructuring expense line. The following table presents a reconciliation of free cash flow to net cash provided by (used in) operating activities, the most directly comparable GAAP measure, for each of the periods indicated (in thousands, unaudited): Three Months Ended October 31, Nine Months Ended October 31, 2024 2023 2024 2023 Net cash used in operating activities $ (16,895) $ (12,743) $ (20,186) $ (20,443) Less: Additions to property and equipment (583) (1,066) (2,645) (3,425) Free cash flow $ (17,478) $ (13,809) $ (22,831) $ (23,868) Net cash (used in) provided by investing activities $ (15,392) $ 14,647 $ 2,885 $ 18,093 Net cash provided by financing activities $ 2,835 $ 3,856 $ 8,766 $ 9,353 Couchbase, Inc. Key Business Metrics (in millions) (unaudited) As of Jan. 31, April 30, July 31, Oct. 31, Jan. 31, April 30, July 31, Oct. 31, 2023 2023 2023 2023 2024 2024 2024 2024 Annual Recurring Revenue $ 163.7 $ 172.2 $ 180.7 $ 188.7 $ 204.2 $ 207.7 $ 214.0 $ 220.3 View original content to download multimedia: https://www.prnewswire.com/news-releases/couchbase-announces-third-quarter-fiscal-2025-financial-results-302321531.html SOURCE Couchbase, Inc. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Leaked recordings reveal secretive church pushing physical punishment of children

Tennis New Zealand Summer Series Gets Underway

NonePrince William's hilariously cheeky three-word nickname revealed by Mike Tindall

The Stakes of the Supreme Court’s Major Trans Rights CaseJahmyr Gibbs has been one of the NFL's top playmakers, helping fuel the Detroit Lions ' No. 1-ranked scoring offense. The second-year running back may have earned himself a scolding from head coach Dan Campbell, however, after a recent social media post appeared to reveal some of the Lions' playbook. Screenshots of a post by Gibbs , which were widely circulated Saturday, appeared to show fellow running back Jermar Jefferson , who's on the Lions' practice squad and shares a position meeting room with Gibbs, while posing or dancing. Behind Jefferson can be seen a whiteboard full of apparent offensive play calls and "drop-back protections," including at least 13 legible code names for specific calls. Asked Saturday about Gibbs' post, Campbell was caught off guard . "Oh I didn't know that," he said, asking the inquiring reporter to repeat the name of the player. "I did not know that. Yeah, I need to check on that then. Did not know that. Yeah, I'd rather our stuff not be out there." The 22-year-old Gibbs has shared touches with fellow back David Montgomery this season, and figures to retain a heavy workload against the Green Bay Packers in Week 14. He's days removed from gaining 87 yards on just nine carries in Detroit's Thanksgiving victory over the rival Chicago Bears , bringing his season rushing total to 973 yards -- already a career high, besting his rookie-year mark of 945.

Teck Resources Ltd. Cl B stock rises Tuesday, still underperforms marketHow to get started with BlueskyTennis New Zealand Summer Series Gets Underway

You’ve discovered some interesting biology and have a set of required parameters, thousands of data points, a budget and a deadline. How can you harness the power of computational chemistry to reach your next milestone faster, and more cost effectively? First-void urine (FVU) is emerging as a valuable sample type offering unique insights into various health conditions in clinical and research settings. Unlike midstream urine, FVU is collected at the start of urination, capturing the initial fraction that contains higher concentrations of cells, proteins, and other biomarkers shed from the urogenital tract. These characteristics make FVU particularly useful for detecting infections, cancers, and other diseases at an early stage. The significance of FVU lies in its potential to revolutionize diagnostic and monitoring practices. By providing a non-invasive, easily obtainable sample, FVU facilitates frequent and convenient testing, which is crucial for early detection and ongoing monitoring of diseases. This eBook delves into the science behind first-void urine, exploring its composition, collection methods, and the latest advancements in its application, as well as other potential applications of urine samples. We will examine how FVU is being utilized in various fields, from infectious disease diagnostics to cancer screening and beyond. The integration of advanced technologies, such as molecular diagnostics and biomarker discovery, enhances the utility of FVU enabling more accurate and comprehensive analyses. Through collaborative efforts and innovative research, the potential of FVU as a diagnostic tool continues to expand, offering new possibilities for improving patient outcomes. This eBook aims to provide a comprehensive overview of first-void urine as a sample type, highlighting its advantages, challenges, and future prospects. By understanding the unique properties and applications of FVU, researchers an better harness its potential to enhance diagnostic accuracy and patient care. Join us as we explore the transformative impact of firstvoid urine in the world of medical diagnostics.